Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Orchid Pharma Gains 11%; BSE HEALTHCARE Index Down 1.6%
Fri, 19 Jul 15:23

Orchid Pharma Gains 11%; BSE HEALTHCARE Index Down 1.6%Image source: hudiemm/www.istockphoto.com

Orchid Pharma share price has zoomed 11% and is presently trading at Rs 1,290.0.

Meanwhile, the BSE HEALTHCARE index is at 38,160.5 (down 1.6%).

Among the top gainers in the BSE HEALTHCARE index today are Jubilant Pharmova (up 2.6%) and ALEMBIC PHARMA (up 0.5%).

SUVEN PHARMACEUTICALS (down 6.4%) and Abbott India (down 4.5%) are among the top losers today.

Over the last one year, Orchid Pharma has moved up from Rs 565.8 to Rs 1,290.0, registering a gain of Rs 724.2 (up 128.0%).

On the other hand, the BSE HEALTHCARE index has moved up from 26,443.1 to 38,160.5, registering a gain of 44.3% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 100.9%), Jubilant Pharmova (up 92.1%) and Lupin (up 91.4%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 80,606.3 (down 0.9%).

The top losers among the BSE Sensex today are Tata Steel (down 5.3%) and JSW Steel (down 4.4%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.

In the meantime, NSE Nifty is at 24,526.6 (down 1.1%). Tata Steel and BPCL are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 66,589.9 to 80,606.3, registering a gain of 14,016.4 points (up 21.0%).

Orchid Pharma Financial Update...

Orchid Pharma net profit fell 49.2% YoY to Rs 335 million for the quarter ended March 2024, compared to a profit of Rs 659 million a year ago. Net sales rose 3.4% to Rs 2,171 million during the period as against Rs 2,099 million in January-March 2023.

For the year ended March 2023, Orchid Pharma reported 197.1% increase in net profit to Rs 552 million compared to net loss of Rs 569 million during FY22. Revenue of the company grew 19.0% to Rs 6,659 million during FY23.

The current Price to earnings ratio of Orchid Pharma, based on rolling 12 month earnings, stands at 69.2.


Equitymaster requests your view! Post a comment on "Orchid Pharma Gains 11%; BSE HEALTHCARE Index Down 1.6%". Click here!